billHRES1301Event Tuesday, May 19, 2026Analyzed

Supporting the designation of May 29, 2026, as "Mental Health Awareness in Agriculture Day" to raise awareness around mental health in the agricultural industry and workforce and to continue to reduce stigma associated with mental illness.

Neutral

Summary

H.Res. 1301 is a non-binding resolution designating May 29, 2026, as 'Mental Health Awareness in Agriculture Day.' It does not authorize or appropriate any funding, create mandates, or impose regulations. The bill is in early legislative stage—referred to committee—with no market impact. No tickers meet the confidence gate for causal linkage because the resolution is purely symbolic.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.H.Res. 1301 is a symbolic, non-binding resolution with zero funding or regulatory impact.
  • 2.No tickers are causally linked—no agricultural or healthcare company faces changed revenue or competitive dynamics.
  • 3.The bill is in early stage (referred to committee) and has no path to material market impact.

Market Implications

No market implications. This is a procedural, non-binding resolution with no link to any publicly traded company's financials. The agricultural and healthcare sectors are not impacted.

Full Analysis

This resolution, H.Res. 1301, was introduced on May 19, 2026, by Rep. Bost and 22 cosponsors. It is a non-binding 'sense of the House' resolution that supports raising awareness about mental health in agriculture. The bill text does not obligate any spending, regulatory change, or tax policy. It is a symbolic statement with no legal or economic force. There is no money trail. The resolution explicitly states 'supports the designation' and 'encourages all to observe.' No funds are authorized or appropriated. Even if enacted, it would not move any market sector. Because this is a non-binding resolution with no mandatory provisions, there is no causal mechanism linking it to any publicly traded company's revenue, costs, or competitive position. The healthcare industry is mentioned only in the context of mental health awareness, not as a beneficiary of contracts or mandates. Agricultural companies are referenced solely as the population the resolution seeks to support, with no financial or regulatory impact. The companion bill S.Res. 727 is identical in the Senate and also at the referral stage, but both chambers' resolutions remain purely aspirational. The next step would be committee consideration, but no further action is scheduled. For retail investors, this resolution has zero material effect on any company's financial performance. No tickers should be associated with it.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.